| CAS NO: | 1478712-37-6 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| Name: BMS-986120 CAS#: 1478712-37-6 Chemical Formula: C23H23N5O5S2 Exact Mass: 513.1141 Molecular Weight: 513.587 | |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Technical Information | Synonym: BMS 986120; BMS-986120; BMS986120. Chemical Name: 4-(4-(((6-methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)benzofuran-4-yl)oxy)methyl)-5-methylthiazol-2-yl)morpholine InChi Key: MINMDCMSHDBHKG-UHFFFAOYSA-N InChi Code: InChI=1S/C23H23N5O5S2/c1-13-17(25-21(34-13)27-4-6-31-7-5-27)12-32-18-8-14(29-2)9-19-15(18)10-20(33-19)16-11-28-22(24-16)35-23(26-28)30-3/h8-11H,4-7,12H2,1-3H3 SMILES Code: COC1=NN2C(S1)=NC(C(O3)=CC4=C3C=C(OC)C=C4OCC(N=C5N6CCOCC6)=C(S5)C)=C2 |
| Target | IC50: 9.5 (PAR4, human), 2.1 nM (PAR4, monkey)[1]. |
|---|---|
| In Vitro | BMS-986120 (BMS) comparably inhibits PA induced by PAR4-AP in human and monkey blood in vitro (IC50 of 9.5±2.7 and 2.1±0.4 nM, respectively)[1]. |
| In Vivo | In monkeys, BMS-986120 produces parallel rightward shifts in the log PA dose response to PAR4-AP without affecting maximum response, suggesting surmountable antagonism. BMS (1 mg/kg) does not inhibit PA induced by PAR1-AP, ADP and collagen, supporting selectivity. BMS (0.2, 0.5, 1 mg/kg) reduces TW by 35±5, 49±4, and 83±4%, respectively. Maximum KBT and MBT increases are only 2.2-fold and 1.8-fold, respectively. A maximum antiplatelet dose of ASA (4 mg/kg/h, n=8) slightly reduces TW by 12±2% and increases KBT and MBT by 2.2- and 2.7-fold, respectively. Co-administration of ASA and BMS (0.5 or 1 mg/kg) reduce TW by 54±3 and 95±2%, increase KBT by 3.1- and 3.6-fold, and increase MBT by 2.6- and 3.3-fold, respectively (n=8/group). In companion monkey studies, clopidogrel (0.3 mg/kg/day, n=6) alone reduces TW by 49±6%, but increases KBT and MBT by 7.3- and 8.1-fold, respectively[1]. |
| Animal Admin | Monkeys[1] Individual anesthetized monkeys are given orally of BMS-986120 (BMS: 0.2, 0.5,1 mg/kg) or vehicle (n=8/group) 2 hour before a combination of thrombosis, BT and ex vivo biomarker experiments. Aspirin alone (ASA, 4 mg/kg/h IV) or in combination with BMS-986120 (0.5, 1 mg/kg) is also studied (n=8/group). Thrombus weight (TW) reduction, BT increase over vehicle in kidney (KBT) and mesenteric artery (MBT), and platelet aggregation (PA) inhibition are determined. Peak PA responses to activation peptides selective for PAR4 (PAR4-AP, 12.5 μM) and PAR1 (PAR1-AP, 18 μM), ADP (20 μM), and collagen (5 μg/mL) are determined by whole blood aggregometry[1]. |
| References | [1]. Abstract 175: A Novel Orally-Active Small-Molecule Antagonist of the Platelet Protease-Activated Receptor-4, BMS-986120, Inhibits Arterial Thrombosis With Limited Impact on Hemostasis in Cynomolgus Monkeys. Stroke. 2018;47:A175. |
m.cnreagent.com